{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T23:45:09Z","timestamp":1785282309330,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:00:00Z","timestamp":1725494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T00:00:00Z","timestamp":1725494400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Hunan Province Young talents Program","award":["2021RC3027"],"award-info":[{"award-number":["2021RC3027"]}]},{"name":"Hunan Province key research and development plan","award":["2023SK2016"],"award-info":[{"award-number":["2023SK2016"]}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2023JJ30870"],"award-info":[{"award-number":["2023JJ30870"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Central South University Innovation-Driven Research Program","award":["2023CXQD071"],"award-info":[{"award-number":["2023CXQD071"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Mol Biol Lett"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Vasculogenic mimicry (VM) is a potential cause of resistance to antiangiogenic therapy and is closely related to the malignant progression of tumors. It has been shown that noncoding RNAs play an important role in the formation of VM in malignant tumors. However, the role of circRNAs in VM of bladder cancer and the regulatory mechanisms are unclear.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Firstly, hsa_circ_0000520 was identified to have circular character by Sanger sequencing and Rnase R assays. Secondly, the potential clinical value of hsa_circ_0000520 was explored by quantitative real-time polymerase chain reaction (qRT-PCR) and fluorescence in situ hybridization (FISH) of clinical specimens. Thirdly, the role of hsa_circ_0000520 in bladder cancer invasion, migration, and VM formation was examined by in vivo and in vitro experiments. Finally, the regulatory mechanisms of hsa_circ_0000520 in the malignant progression of bladder cancer were elucidated by RNA binding protein immunoprecipitation (RIP), RNA pulldown, co-immunoprecipitation (co-IP), qRT-PCR, Western blot (WB), and fluorescence co-localization.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Hsa_circ_0000520 was characterized as a circular RNA and was lowly expressed in bladder cancer compared with the paracancer. Bladder cancer patients with high expression of hsa_circ_0000520 had better survival prognosis. Functionally, hsa_circ_0000520 inhibited bladder cancer invasion, migration, and VM formation. Mechanistically, hsa_circ_0000520 acted as a scaffold to promote binding of UBE2V1\/UBC13 to Lin28a, further promoting the ubiquitous degradation of Lin28a, improving PTEN mRNA stability, and inhibiting the phosphorylation of the PI3K\/AKT pathway. The formation of hsa_circ_0000520 in bladder cancer was regulated by RNA binding protein QKI.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Hsa_circ_0000520 inhibits metastasis and VM formation in bladder cancer and is a potential target for bladder cancer diagnosis and treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s11658-024-00627-0","type":"journal-article","created":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T15:19:52Z","timestamp":1725549592000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Hsa_circ_0000520 suppresses vasculogenic mimicry formation and metastasis in bladder cancer through Lin28a\/PTEN\/PI3K signaling"],"prefix":"10.1186","volume":"29","author":[{"given":"Chunyu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiatong","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenglin","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunbo","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zicheng","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinliang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haisu","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benyi","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinbo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiongbing","family":"Zu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,5]]},"reference":[{"key":"627_CR1","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1016\/s0140-6736(22)01188-6","volume":"400","author":"E Comp\u00e9rat","year":"2022","unstructured":"Comp\u00e9rat E, Amin MB, Cathomas R, Choudhury A, De Santis M, Kamat A, Stenzl A, Thoeny HC, Witjes JA. Current best practice for bladder cancer: a narrative review of diagnostics and treatments. Lancet. 2022;400:1712\u201321. https:\/\/doi.org\/10.1016\/s0140-6736(22)01188-6.","journal-title":"Lancet"},{"key":"627_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348. https:\/\/doi.org\/10.3322\/caac.21763.","journal-title":"CA Cancer J Clin"},{"key":"627_CR3","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41568-020-00313-1","volume":"21","author":"L Tran","year":"2021","unstructured":"Tran L, Xiao JF, Agarwal N, Duex JE, Theodorescu D. Advances in bladder cancer biology and therapy. Nat Rev Cancer. 2021;21:104\u201321. https:\/\/doi.org\/10.1038\/s41568-020-00313-1.","journal-title":"Nat Rev Cancer"},{"key":"627_CR4","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1517\/13543784.2015.1041588","volume":"24","author":"CR Mazzola","year":"2015","unstructured":"Mazzola CR, Chin J. Targeting the VEGF pathway in metastatic bladder cancer. Expert Opin Investig Drugs. 2015;24:913\u201327. https:\/\/doi.org\/10.1517\/13543784.2015.1041588.","journal-title":"Expert Opin Investig Drugs"},{"key":"627_CR5","doi-asserted-by":"publisher","first-page":"2646","DOI":"10.1093\/annonc\/mdr023","volume":"22","author":"J Bellmunt","year":"2011","unstructured":"Bellmunt J, Gonz\u00e1lez-Larriba JL, Prior C, Maroto P, Carles J, Castellano D, Mellado B, Gallardo E, Perez-Gracia JL, Aguilar G, Villanueva X, Albanell J, Calvo A. Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity. Ann Oncol. 2011;22:2646\u201353. https:\/\/doi.org\/10.1093\/annonc\/mdr023.","journal-title":"Ann Oncol"},{"key":"627_CR6","doi-asserted-by":"publisher","first-page":"4090","DOI":"10.1002\/cncr.24467","volume":"115","author":"R Dreicer","year":"2009","unstructured":"Dreicer R, Li H, Stein M, DiPaola R, Eleff M, Roth BJ, Wilding G. Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group. Cancer. 2009;115:4090\u20135. https:\/\/doi.org\/10.1002\/cncr.24467.","journal-title":"Cancer"},{"key":"627_CR7","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.eururo.2011.05.034","volume":"60","author":"DJ Gallagher","year":"2011","unstructured":"Gallagher DJ, Al-Ahmadie H, Ostrovnaya I, Gerst SR, Regazzi A, Garcia-Grossman I, Riches J, Gounder SK, Flaherty AM, Trout A, Milowsky MI, Bajorin DF. Sunitinib in urothelial cancer: clinical, pharmacokinetic, and immunohistochemical study of predictors of response. Eur Urol. 2011;60:344\u20139. https:\/\/doi.org\/10.1016\/j.eururo.2011.05.034.","journal-title":"Eur Urol"},{"key":"627_CR8","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/s1470-2045(12)70294-2","volume":"13","author":"A Necchi","year":"2012","unstructured":"Necchi A, Mariani L, Zaffaroni N, Schwartz LH, Giannatempo P, Crippa F, Morosi C, Lanocita R, Sava T, Ortega C, Messina C, Sacco C, Pennati M, Daidone MG, Nicolai N, De Braud F, Gianni AM, Salvioni R. Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. Lancet Oncol. 2012;13:810\u20136. https:\/\/doi.org\/10.1016\/s1470-2045(12)70294-2.","journal-title":"Lancet Oncol"},{"key":"627_CR9","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.cell.2011.08.039","volume":"146","author":"M Potente","year":"2011","unstructured":"Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell. 2011;146:873\u201387. https:\/\/doi.org\/10.1016\/j.cell.2011.08.039.","journal-title":"Cell"},{"key":"627_CR10","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nrc.2017.51","volume":"17","author":"M De Palma","year":"2017","unstructured":"De Palma M, Biziato D, Petrova TV. Microenvironmental regulation of tumour angiogenesis. Nat Rev Cancer. 2017;17:457\u201374. https:\/\/doi.org\/10.1038\/nrc.2017.51.","journal-title":"Nat Rev Cancer"},{"key":"627_CR11","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/s0002-9440(10)65173-5","volume":"155","author":"AJ Maniotis","year":"1999","unstructured":"Maniotis AJ, Folberg R, Hess A, Seftor EA, Gardner LM, Pe\u2019er J, Trent JM, Meltzer PS, Hendrix MJ. Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am J Pathol. 1999;155:739\u201352. https:\/\/doi.org\/10.1016\/s0002-9440(10)65173-5.","journal-title":"Am J Pathol"},{"key":"627_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111244","volume":"137","author":"H Gan","year":"2021","unstructured":"Gan H, Lei Y, Yuan N, Tang K, Hao W, Ma Q, Wu M, Zhou X, Li X, Huang J, Deng L, Chen J. Circular RNAs in depression: Biogenesis, function, expression, and therapeutic potential. Biomed Pharmacother. 2021;137: 111244. https:\/\/doi.org\/10.1016\/j.biopha.2021.111244.","journal-title":"Biomed Pharmacother"},{"key":"627_CR13","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.cell.2018.12.021","volume":"176","author":"JN Vo","year":"2019","unstructured":"Vo JN, Cieslik M, Zhang Y, Shukla S, Xiao L, Zhang Y, Wu YM, Dhanasekaran SM, Engelke CG, Cao X, Robinson DR, Nesvizhskii AI, Chinnaiyan AM. The landscape of circular RNA in cancer. Cell. 2019;176:869-881.e813. https:\/\/doi.org\/10.1016\/j.cell.2018.12.021.","journal-title":"Cell"},{"key":"627_CR14","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2217\/pme-2020-0103","volume":"17","author":"M Papatsirou","year":"2020","unstructured":"Papatsirou M, Artemaki PI, Scorilas A, Kontos CK. The role of circular RNAs in therapy resistance of patients with solid tumors. Pers Med. 2020;17:469\u201390. https:\/\/doi.org\/10.2217\/pme-2020-0103.","journal-title":"Pers Med"},{"key":"627_CR15","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1038\/s41388-019-1092-z","volume":"39","author":"F Liu","year":"2020","unstructured":"Liu F, Zhang H, Xie F, Tao D, Xiao X, Huang C, Wang M, Gu C, Zhang X, Jiang G. Hsa_circ_0001361 promotes bladder cancer invasion and metastasis through miR-491\u20135p\/MMP9 axis. Oncogene. 2020;39:1696\u2013709. https:\/\/doi.org\/10.1038\/s41388-019-1092-z.","journal-title":"Oncogene"},{"key":"627_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2024.111164","volume":"119","author":"F Lyu","year":"2024","unstructured":"Lyu F, Huang S, Yan Z, He Q, Liu C, Cheng L, Cong Y, Chen K, Song Y, Xing Y. CircUGGT2 facilitates progression and cisplatin resistance of bladder cancer through nonhomologous end-joining pathway. Cell Signal. 2024;119: 111164. https:\/\/doi.org\/10.1016\/j.cellsig.2024.111164.","journal-title":"Cell Signal"},{"key":"627_CR17","doi-asserted-by":"publisher","DOI":"10.15252\/embr.201948467","volume":"21","author":"J Chen","year":"2020","unstructured":"Chen J, Sun Y, Ou Z, Yeh S, Huang CP, You B, Tsai YC, Sheu TJ, Zu X, Chang C. Androgen receptor-regulated circFNTA activates KRAS signaling to promote bladder cancer invasion. EMBO Rep. 2020;21: e48467. https:\/\/doi.org\/10.15252\/embr.201948467.","journal-title":"EMBO Rep"},{"key":"627_CR18","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13045-018-0638-9","volume":"11","author":"T Shen","year":"2018","unstructured":"Shen T, Cai LD, Liu YH, Li S, Gan WJ, Li XM, Wang JR, Guo PD, Zhou Q, Lu XX, Sun LN, Li JM. Ube2v1-mediated ubiquitination and degradation of Sirt1 promotes metastasis of colorectal cancer by epigenetically suppressing autophagy. J Hematol Oncol. 2018;11:95. https:\/\/doi.org\/10.1186\/s13045-018-0638-9.","journal-title":"J Hematol Oncol"},{"key":"627_CR19","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1182\/blood-2012-02-406074","volume":"120","author":"M Pulvino","year":"2012","unstructured":"Pulvino M, Liang Y, Oleksyn D, DeRan M, Van Pelt E, Shapiro J, Sanz I, Chen L, Zhao J. Inhibition of proliferation and survival of diffuse large B-cell lymphoma cells by a small-molecule inhibitor of the ubiquitin-conjugating enzyme Ubc13-Uev1A. Blood. 2012;120:1668\u201377. https:\/\/doi.org\/10.1182\/blood-2012-02-406074.","journal-title":"Blood"},{"key":"627_CR20","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13045-022-01345-w","volume":"15","author":"X Wang","year":"2022","unstructured":"Wang X, Chen T, Li C, Li W, Zhou X, Li Y, Luo D, Zhang N, Chen B, Wang L, Zhao W, Fu S, Yang Q. CircRNA-CREIT inhibits stress granule assembly and overcomes doxorubicin resistance in TNBC by destabilizing PKR. J Hematol Oncol. 2022;15:122. https:\/\/doi.org\/10.1186\/s13045-022-01345-w.","journal-title":"J Hematol Oncol"},{"key":"627_CR21","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1186\/s12915-017-0444-9","volume":"15","author":"NR Choudhury","year":"2017","unstructured":"Choudhury NR, Heikel G, Trubitsyna M, Kubik P, Nowak JS, Webb S, Granneman S, Spanos C, Rappsilber J, Castello A, Michlewski G. RNA-binding activity of TRIM25 is mediated by its PRY\/SPRY domain and is required for ubiquitination. BMC Biol. 2017;15:105. https:\/\/doi.org\/10.1186\/s12915-017-0444-9.","journal-title":"BMC Biol"},{"key":"627_CR22","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1038\/s41388-022-02198-w","volume":"41","author":"H Zou","year":"2022","unstructured":"Zou H, Luo J, Guo Y, Liu Y, Wang Y, Deng L, Li P. RNA-binding protein complex LIN28\/MSI2 enhances cancer stem cell-like properties by modulating Hippo-YAP1 signaling and independently of Let-7. Oncogene. 2022;41:1657\u201372. https:\/\/doi.org\/10.1038\/s41388-022-02198-w.","journal-title":"Oncogene"},{"key":"627_CR23","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.molcel.2015.11.020","volume":"61","author":"Y Zeng","year":"2016","unstructured":"Zeng Y, Yao B, Shin J, Lin L, Kim N, Song Q, Liu S, Su Y, Guo JU, Huang L, Wan J, Wu H, Qian J, Cheng X, Zhu H, Ming GL, Jin P, Song H. Lin28A binds active promoters and recruits Tet1 to regulate gene expression. Mol Cell. 2016;61:153\u201360. https:\/\/doi.org\/10.1016\/j.molcel.2015.11.020.","journal-title":"Mol Cell"},{"key":"627_CR24","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013.","journal-title":"Cell"},{"key":"627_CR25","doi-asserted-by":"publisher","first-page":"2016","DOI":"10.1016\/j.cell.2022.04.021","volume":"185","author":"CX Liu","year":"2022","unstructured":"Liu CX, Chen LL. Circular RNAs: characterization, cellular roles, and applications. Cell. 2022;185:2016\u201334. https:\/\/doi.org\/10.1016\/j.cell.2022.04.021.","journal-title":"Cell"},{"key":"627_CR26","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41467-020-20527-z","volume":"12","author":"B Li","year":"2021","unstructured":"Li B, Zhu L, Lu C, Wang C, Wang H, Jin H, Ma X, Cheng Z, Yu C, Wang S, Zuo Q, Zhou Y, Wang J, Yang C, Lv Y, Jiang L, Qin W. circNDUFB2 inhibits non-small cell lung cancer progression via destabilizing IGF2BPs and activating anti-tumor immunity. Nat Commun. 2021;12:295. https:\/\/doi.org\/10.1038\/s41467-020-20527-z.","journal-title":"Nat Commun"},{"key":"627_CR27","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1038\/nature08909","volume":"463","author":"TW Nilsen","year":"2010","unstructured":"Nilsen TW, Graveley BR. Expansion of the eukaryotic proteome by alternative splicing. Nature. 2010;463:457\u201363. https:\/\/doi.org\/10.1038\/nature08909.","journal-title":"Nature"},{"key":"627_CR28","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1161\/circresaha.113.301302","volume":"113","author":"EP van der Veer","year":"2013","unstructured":"van der Veer EP, de Bruin RG, Kraaijeveld AO, de Vries MR, Bot I, Pera T, Segers FM, Trompet S, van Gils JM, Roeten MK, Beckers CM, van Santbrink PJ, Janssen A, van Solingen C, Swildens J, de Boer HC, Peters EA, Bijkerk R, Rousch M, Doop M, Kuiper J, Schalij MJ, van der Wal AC, Richard S, van Berkel TJ, Pickering JG, Hiemstra PS, Goumans MJ, Rabelink TJ, de Vries AA, Quax PH, Jukema JW, Biessen EA, van Zonneveld AJ. Quaking, an RNA-binding protein, is a critical regulator of vascular smooth muscle cell phenotype. Circ Res. 2013;113:1065\u201375. https:\/\/doi.org\/10.1161\/circresaha.113.301302.","journal-title":"Circ Res"},{"key":"627_CR29","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1101\/gad.251926.114","volume":"28","author":"D Liang","year":"2014","unstructured":"Liang D, Wilusz JE. Short intronic repeat sequences facilitate circular RNA production. Genes Dev. 2014;28:2233\u201347. https:\/\/doi.org\/10.1101\/gad.251926.114.","journal-title":"Genes Dev"},{"key":"627_CR30","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12943-022-01615-8","volume":"21","author":"Y Xi","year":"2022","unstructured":"Xi Y, Shen Y, Wu D, Zhang J, Lin C, Wang L, Yu C, Yu B, Shen W. CircBCAR3 accelerates esophageal cancer tumorigenesis and metastasis via sponging miR-27a-3p. Mol Cancer. 2022;21:145. https:\/\/doi.org\/10.1186\/s12943-022-01615-8.","journal-title":"Mol Cancer"},{"key":"627_CR31","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.cell.2014.09.001","volume":"159","author":"XO Zhang","year":"2014","unstructured":"Zhang XO, Wang HB, Zhang Y, Lu X, Chen LL, Yang L. Complementary sequence-mediated exon circularization. Cell. 2014;159:134\u201347. https:\/\/doi.org\/10.1016\/j.cell.2014.09.001.","journal-title":"Cell"},{"key":"627_CR32","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.molcel.2021.11.019","volume":"82","author":"CX Liu","year":"2022","unstructured":"Liu CX, Guo SK, Nan F, Xu YF, Yang L, Chen LL. RNA circles with minimized immunogenicity as potent PKR inhibitors. Mol Cell. 2022;82:420-434.e426. https:\/\/doi.org\/10.1016\/j.molcel.2021.11.019.","journal-title":"Mol Cell"}],"container-title":["Cellular &amp; Molecular Biology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11658-024-00627-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s11658-024-00627-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s11658-024-00627-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T07:02:17Z","timestamp":1725606137000},"score":1,"resource":{"primary":{"URL":"https:\/\/cmbl.biomedcentral.com\/articles\/10.1186\/s11658-024-00627-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,5]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["627"],"URL":"https:\/\/doi.org\/10.1186\/s11658-024-00627-0","relation":{},"ISSN":["1689-1392"],"issn-type":[{"value":"1689-1392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,5]]},"assertion":[{"value":"15 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Committee of Xiangya hospital (approval no. 202211103, date: 10.30.2022) based on the Helsinki Declaration. All animal experiments were approved by the Animal Ethics Committee of Xiangya hospital (approval no. 202211103, date 10.30.2022) and were performed according to the international guidelines and the Basel Declaration.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"We also confirm that all the listed authors have participated actively in the study, and have seen and approved the submitted manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors do not have any possible conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"118"}}